Clinical Genomics
Development and implementation of molecular diagnostic technologies and genomic testing.
COMPANY · SCIENTIFIC LEADERSHIP
Scientific Advisory Board
Scientific expertise across molecular diagnostics, liquid biopsy, cancer genomics, pathology, and precision medicine.
The nRichDX Scientific Advisory Board brings together experienced scientific and clinical leaders whose work spans molecular pathology, circulating tumor cells, circulating nucleic acids, genomic oncology, and personalized cancer medicine.
03
SCIENTIFIC ADVISORS
Molecular Diagnostics
Liquid Biopsy
Pathology
Genomics
Precision Medicine
SCIENTIFIC GUIDANCE
Expertise where science meets the clinic.
SCIENTIFIC GUIDANCE
Connected to the science shaping liquid biopsy.
The Scientific Advisory Board provides nRichDX with perspective rooted in clinical molecular diagnostics, cancer biology, pathology, and translational research.
Its members bring experience across circulating tumor cells, circulating nucleic acids, genomic oncology, targeted therapy, hematopathology, personalized medicine, and clinical laboratory practice.
AREAS OF EXPERTISE
Scientific perspective across the liquid biopsy continuum.
The board spans complementary disciplines that connect molecular recovery with downstream clinical and translational research.
CTCs & Circulating Nucleic Acids
Research spanning circulating tumor cells, ctDNA, and other circulating biomarkers.
Molecular & Hematopathology
Clinical pathology, hematologic malignancies, and molecular genetic diagnostics.
Personalized Cancer Care
Targeted therapy, genomic oncology, and research focused on individual tumor biology.
SCIENTIFIC ADVISORY BOARD
Meet the scientific advisors.
Scientific and clinical leaders with expertise spanning molecular diagnostics, liquid biopsy, pathology, genomics, and cancer research.
Gregory J. Tsongalis, PhD, HCLD, CC
Chairman, Scientific Advisory Board
Director - Laboratory for Clinical Genomics and Advanced Technology
Professor of Pathology
Audrey and Theodor Geisel School of Medicine at Dartmouth
Dartmouth-Hitchcock Medical Center · Norris Cotton Cancer Center
Dr. Greg Tsongalis is the Director of the Laboratory for Clinical Genomics and Advanced Technology (CGAT) at the Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center (NCCC) in Lebanon, NH and a Professor of Pathology and Laboratory Medicine at the Audrey and Theodor Geisel School of Medicine at Dartmouth in Hanover, NH. He is a member of the NCCC Molecular Therapeutics Program and the gastrointestinal and breast cancer clinical oncology groups. In 2016 he became a member of Dartmouth College’s Program in Experimental and Molecular Medicine (PEMM), and he has served on the advisory board of the Health Care Genetics Professional Science Master’s Degree Program at the University of Connecticut (Storrs, CT). His area of expertise is in the development and implementation of clinical molecular diagnostic technologies. His research interests are in the pathogenesis of human cancers, personalized medicine and disruptive technologies. He has authored/edited twelve textbooks in the field of molecular pathology, published more than 200 peer reviewed manuscripts, and has been an invited speaker at both national and international meetings. He has served on numerous committees of the AACC, ASIP, FASEB and AMP where he is a past President. He is active in the Alliance for Clinical Trials in Oncology, the Association for Molecular Pathology, the American Association for Clinical Chemistry, the American Association of Bioanalysts, and the American Society for Investigative Pathology. He serves on the editorial boards of 8 journals including Clinical Chemistry, Experimental and Molecular Pathology, and the Journal of Molecular Diagnostics. He also serves on numerous corporate scientific advisory boards.
Daniel Kim, PhD
Scientific Advisory Board Member
Assistant Professor, University of California, Santa Cruz
Associate Member, Canary Center at Stanford for Cancer Early Detection
Research Scholar, American Cancer Society
Dr. Daniel Kim is an internationally recognized leader in RNA liquid biopsy technology development for the early detection of cancer and other diseases. Dr. Kim directs a multidisciplinary research group as an Assistant Professor at the University of California, Santa Cruz and is also an Associate Member of the Canary Center at Stanford for Cancer Early Detection and a Research Scholar of the American Cancer Society. Dr. Kim serves as Co-Chair of the National Institutes of Health (NIH) Liquid Biopsy Scientific Interest Group and Co-Chair of the International Society for Extracellular Vesicles (ISEV) RNA Task Force. Dr. Kim's pioneering research has been featured in Newsweek, Scientific American, and by the NIH Director and has also been recognized by awards from the Damon Runyon Cancer Research Foundation and the National Academy of Sciences.
Klaus Pantel, MD, PhD
Scientific Advisory Board Member
Chairman of the Institute of Tumour Biology
University Medical Center Hamburg-Eppendorf
Founder and Chairman of the European Liquid Biopsy Society (ELBS)
Prof. Klaus Pantel is chairman of the Institute of Tumour Biology at the University Medical Center Hamburg-Eppendorf. He graduated in 1986, and after his postdoctoral period in the USA he performed research at the Institute of Immunology, University of Munich for 10 years. The pioneer work of Prof. Pantel in the field of cancer micrometastasis, circulating tumor cells and circulating nucleic acids is reflected by more than 550 publications in excellent high ranking biomedical and scientific journals and has been awarded the AACR Outstanding Investigator Award 2010, German Cancer Award 2010, and two ERC Advanced Investigator Grants 2011 and 2019. Moreover, Prof. Pantel is the founder and chairman of the European Liquid Biopsy Society (ELBS).
FROM MOLECULAR RECOVERY TO CLINICAL RESEARCH
Scientific credibility begins with understanding the entire workflow.
The disciplines represented on the Scientific Advisory Board span both the upstream and downstream sides of liquid biopsy: sample preparation, biomarker recovery, molecular diagnostics, genomic analysis, pathology, and clinical research.
Explore Scientific Reference Materials
01
Sample
02
Recovery
03
Molecular Analysis
04
Clinical Research
MORE nRichDX LEADERSHIP
Explore the people guiding nRichDX.
Continue through the leadership and company pages to learn more about the people shaping nRichDX.
SCIENCE AT THE CENTER